David Delaney Form 3 Pasithea Therapeutics / David Delaney ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Delaney David

(Last) (First) (Middle)

C/O CONCORD INVESTMENT PARTNERS LTD.

60 ST. CLAIR AVENUE EAST, SUITE 702

(Street)

TORONTO A6 M4T 1N5

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/09/2022

3. Issuer Name and Ticker or Trading Symbol
Pasithea Therapeutics Corp. [ KTTA ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
Member of 10% owner group

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	226,521	I	See footnote(1)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

1. Name and Address of Reporting Person^*

Delaney David

(Last) (First) (Middle)

C/O CONCORD INVESTMENT PARTNERS LTD.

60 ST. CLAIR AVENUE EAST, SUITE 702

(Street)

TORONTO A6 M4T 1N5

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Concord IP2 Ltd.

(Last) (First) (Middle)

C/O CONCORD INVESTMENT PARTNERS LTD.

60 ST. CLAIR AVENUE EAST, SUITE 702

(Street)

TORONTO A6 M4T 1N5

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Elderhill Corp

(Last) (First) (Middle)

C/O CONCORD INVESTMENT PARTNERS LTD.

60 ST. CLAIR AVENUE EAST, SUITE 702

(Street)

TORONTO A6 M4T IN5

(City) (State) (Zip)

Explanation of Responses:

1. 191,321 shares are held by Concord IP2, Ltd., of which David Delaney serves as sole director and President, and 35,200 shares are held by Elderhill Corporation, of which David Delaney serves as sole director and President.

	/s/ David Delaney	08/16/2022
	/s/ David Delaney, President of Concord IP2 Ltd.	08/16/2022
	/s/ David Delaney, President of Elderhill Corporation	08/16/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.